Page 45 - IACC Newsletter August-September 2013 Issue 13

Basic HTML Version

Dhir and Kaul are now putting the next piece of their strategy in place. Apple wants to enter smaller Indian cities and
towns with iPhones, iPads and iPods as it feels these markets can deliver on its bid to grow fast. "Apple has realised that
if it wants to grow fast in India, it has to look beyond the metros," said the CEO of one of India's retail chains. "The
company wants to grow upwards of 30% year-on-year in India and feels the smaller markets would play a critical role
since the aspiration level of Apple products amongst the youth and rich is growing there as well."
Dhir joined Apple India three years ago from AOL Inc, where he was the global head for international business, and
changed the way Apple was doing business in the country. He hired Kaul from BlackBerry India, expanded the team
threefold to more than 150 executives, strengthened the Apple exclusive stores network, shortened the gap between
the launch of new models overseas and in India and spearheaded the company's thrust on iPhones.
Apple CEO Tim Cook acknowledged the importance of India for the first time in July while announcing the April-June
results, declaring that iPhone sales in the country grew 400% during the quarter, albeit on a small base. The company
also reported double-digit growth in India's iPad sales.
The new marketing vision for India was unveiled on Monday evening at a meeting with 20 CEOs and senior executives of
the country's top multi-brand telecom and electronic retail chains. Apple India's senior executives spelt out plans to
enter the top 50 tier II and III markets in India by selling its phones, tablets and portable music players at their outlets in
an exclusive corner or a shop-in-shop, said three people who attended the meeting. They requested anonymity since
Apple officials had asked them to keep details of the meeting confidential.
Copyright © 2013, Bennett, Coleman & Co. Ltd. All Rights Reserved.
Ashwagandha gets US patent for vaccine adjuvant
A group of researchers from Pune University and Serum Institute have received a patent on the use of Ashwagandha as
a vaccine adjuvant, or component that helps improve its efficacy.
A medicinal herb, Ashwagandha is also referred to as Indian Gensing.
In a project supported by the Department of Science and Technology, the research was part of a project to develop
“botanical immunomodulators” as adjuvants to improve vaccine efficacy, said a researcher from Serum.
In the past, the industry used aluminium salts as an adjuvant, but as newer vaccines are developed, industry is also
looking for alternatives, he added.
In fact, the finding would be used in new vaccines such as the pentavalent vaccine targeting meningitis, or those against
dengue and pneumococcal diseases, said Serum Executive Director Suresh Jadhav.
About nine herbs were studied, before research found the required property in ashwagandha (Withania somnifera) and
more work was done to understand in what ratio it could be used in a vaccine, a researcher said.
Unlike earlier instances where companies tried to patent turmeric, for example, the researcher clarified, the patent here
was in an area not claimed by ayurveda.
VACCINE APPLICATIONS
Further, he said that all known claims on herbs have been digitized and a patent would not have been granted in the US,
if the latest claim was similar to existing knowledge in India or China.
The adjuvant showed properties where it could be used with other licensed adjuvants in T-cell dependent antigens such
as diphtheria, tetanus and pertusssis group of vaccines.
The project was supported by DST and Serum Institute of India with total financial outlay of Rs 90 lakh spread over 3
years.